MARKSANS vs TORNTPHARM: Stock Comparison

Marksans Pharma Limited vs Torrent Pharmaceuticals Limited

Live data: 22 July 2026, 2:59 PM IST • Source: NSE and company filings

Torrent Pharmaceuticals Limited is the larger company by market capitalisation. Marksans Pharma Limited shows a lower P/E, lower leverage and a higher ROCE, while Torrent Pharmaceuticals Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Marksans Pharma Limited and Torrent Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MARKSANS is more favourable on 6 of 13 scored metrics and TORNTPHARM on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
TORNTPHARM is the larger company
₹1.69 L Cr vs ₹10,928 Cr
P/E Ratio
MARKSANS has a lower P/E
28.31x vs 78.84x
P/B Ratio
MARKSANS has a lower P/B
3.91x vs 20.33x
EPS
TORNTPHARM has higher earnings per share
₹63.75 vs ₹9.71
Dividend Yield
TORNTPHARM has a higher dividend yield
0.9% vs 0.29%
Revenue Growth (TTM YoY)
TORNTPHARM has faster revenue growth
41.8% vs 20.8%
EPS Growth (TTM YoY)
MARKSANS has faster EPS growth
63.5% vs -21.7%
Qtr Sales Growth
TORNTPHARM has stronger quarterly sales growth
41.8% vs 20.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMARKSANSTORNTPHARM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMARKSANSTORNTPHARM
Live Price₹241.1₹5,013.2
Day Change-7.38%-0.55%
Volume37.45 L2.16 L
52-Week High₹281.6₹5,085.8
52-Week Low₹155₹3,468
Distance from 52W High-14.38%-1.43%

Valuation

MetricMARKSANSTORNTPHARM
Market Cap₹10,928 Cr₹1.69 L Cr
P/E Ratio28.31x78.84x
P/B Ratio3.91x20.33x
EPS₹9.71₹63.75
Book Value₹66.74₹247.85
Dividend Yield0.29%0.9%

Growth

MetricMARKSANSTORNTPHARM
Revenue Growth (TTM YoY)20.8%41.8%
EPS Growth (TTM YoY)63.5%-21.7%
Qtr Sales Growth20.8%41.8%
Qtr Profit Growth63.6%-20.6%

Profitability & Leverage

MetricMARKSANSTORNTPHARM
ROE15.2%16.99%
ROCE18.8%15.2%
Net Margin14.16%15.73%
Operating Margin20.4%25.01%
Debt to Equity0.11x85.45x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricMARKSANSTORNTPHARM
Promoter Holding43.87%68.31%
FII Holding16.76% 8.64 pp16.18% 0.05 pp
DII Holding6.57% 0.66 pp9.06% 0.08 pp
Public Holding32.79% 9.3 pp6.45% 0.03 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Marksans Pharma Limited and Torrent Pharmaceuticals Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.